RxDoctor Payments DataLook up a doctor →

Todd Alekshun, MD

Hematology & Oncology · Hartford, CTNPI 1558495689

Payments from drug & device makers

$115,391in general payments, 2019–2025

Across 305 payments — averaging $378.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$93K
  • AstraZeneca$18K
  • Johnson & Johnson$535
  • Genentech USA, Inc.$432
  • Novartis$425
  • Pfizer$392
  • plus $2K from 37 others

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck33$93,399
AstraZeneca(2 entities)25$17,898
Johnson & Johnson(2 entities)38$535
Genentech USA, Inc.31$432
Novartis30$425
Pfizer27$392
Bayer7$226
Sanofi-aventis U.S. LLC3$188
Bristol Myers Squibb10$153
Abbott1$135
Amgen9$128
Sanofi7$116
AMAG Pharmaceuticals, Inc.5$82
Exelixis Inc.5$79
Lilly USA, LLC5$76
Astellas Pharma US Inc3$74
Gilead(2 entities)5$72
Pharmacyclics LLC, An Abbvie Company4$70
Array Biopharma Inc3$67
Eisai Inc.5$66
Takeda Pharmaceuticals U.S.A., Inc.4$66
Clovis Oncology, Inc.4$65
Helsinn Therapeutics (U.S.), Inc.4$54
Incyte Corporation3$52
Jazz Pharmaceuticals Inc.3$51
Seagen Inc.3$51
Ipsen Biopharmaceuticals, Inc3$49
AbbVie3$45
Karyopharm Therapeutics Inc.3$40
Verastem, Inc.2$40
Boehringer Ingelheim2$31
Kyowa Kirin, Inc.2$30
Daiichi Sankyo Inc.2$29
EMD Serono, Inc.2$25
Taiho Oncology, Inc.1$25
Puma Biotechnology, Inc.1$19
Dendreon Pharmaceuticals LLC1$19
Regeneron Healthcare Solutions, Inc.1$17
Heron Therapeutics, Inc.1$16
Tesaro, Inc.1$16
Fortovia Therapeutics, Inc.1$15
Therapeuticsmd, Inc.1$12
Tersera Therapeutics LLC1$11

How this compares

$115,391 in reported general payments places this provider in the 70th percentile of 163 hematology & oncology providers in Connecticut.

See all hematology & oncology providers in Connecticut →

Medicare billing

Part B allowed, 2024
$143,513
Medicare patients
317
Services billed
1,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Hartford

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →